Abstract:Elevated blood levels of low-density lipoprotein cholesterol are a major cardiovascular risk factor, and cholesterol-lowering drugs are among the most prescribed drugs worldwide. Cancer is the second leading cause of death after cardiovascular diseases. The relationship between cancer development and statins intake is controversial, and there are no clear studies in Lebanon and the Middle East concerning this topic. Hence, our study aimed to search for any possible association of statin intake as well as other medications (proton pump inhibitors [PPI], metformin, Aspirin, Angiotensin-Converting Enzyme inhibitors, and fenofibrate) with lung, colorectal cancer (CRC), and bladder cancer development in the Lebanese population. A retrospective study was performed on 709 subjects divided into 2 main groups: control (no cancer ± statin intake), and cases (either lung, or colorectal, or bladder cancer ± statin intake). Collected data included the age and gender of the patient, socioeconomic status, presence of cardiovascular disease and comorbidities, cancer risk factors, and the intake type, dose, and duration of statins. Bivariate, multivariate, and binary logistic analyses were enrolled. Out of 709 participants, 63.2% were males and 75% were cancer-positive (24.1%: lung cancer, 26.7%: CRC, 24.1%: bladder cancer). The overall intake of statins was not shown to significantly affect cancer development. However, a duration-response relationship was established between Simvastatin and lung cancer (odds ratio [OR]=1.208) as well as bladder cancer (OR=1.189). No significant association was found between each statin and CRC. Although PPIs intake was associated with a possibly harmful effect on lung cancer development (OR=3.42), it revealed a protective association with CRC development (OR=0.38). Other risk factors such as smoking and age were strongly associated (harmful) with lung and bladder cancer development. Physical inactivity and a family history of CRC were each associated with a harmful effect on CRC development. A harmful association with the development of lung and bladder cancer was found with the increasing duration of intake of Simvastatin. Other drugs such as PPIs and specific risk factors were also associated negatively or positively with the development of these 3 cancers. These findings should be validated by further investigations to guide clinicians on optimal treatment options for their patients.

5-Aminosalicylic Acid and Statin Use Are Associated with Reduced Risk of Cancers in Patients with Inflammatory Bowel Disease: A Population-Based Cohort Study

Assessing Oral Medication Adherence and Identifying Predictors of Low Adherence in Chinese Inflammatory Bowel Disease Patients

Inflammatory Bowel Disease and Long-term Risk of Cancer: A Prospective Cohort Study among Half a Million Adults in UK Biobank

Statin Use is Associated with Improved Prognosis of Colorectal Cancer in Taiwan.

Regular Statin Users and Colorectal Cancer (CRC) Prognosis.

Cancer Risk In 2621 Chinese Patients With Inflammatory Bowel Disease: A Population-Based Cohort Study

S1229 Investigating the Association Between Statin Use and Cholangiocarcinoma Incidence in Patients With Inflammatory Bowel Disease: Insights From a Retrospective Cohort Analysis

No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study

S1405 Patients With Inflammatory Bowel Disease Who Have Low Socioeconomic Status Have Higher Rates of Complications: A Population-Based Multi-Network Analysis

S1381 Statins and the Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases: A Systemic Review and Meta-Analysis

P665 Statins use and the risk of colorectal cancer in patients with inflammatory bowel disease: A Systematic review and meta-analysis

Regular use of aspirin and statins reduces the risk of cancer in individuals with systemic inflammatory diseases

S1414 Immunomodulator Therapy is Associated With Higher Incidence of Primary Sclerosing Cholangitis and Colorectal Cancer Compared to Biologic Therapy: A Propensity-Matched Cohort Study

Risk of Surgical Site Infection (SSI) following Colorectal Resection Is Higher in Patients With Disseminated Cancer: An NCCN Member Cohort Study

Statin use is associated with reduction in risk of de novo primary sclerosing cholangitis among patients with inflammatory bowel disease: A National Database Study

New Understanding of Mechanisms of Action of 5-Aminosalicylic Acid in Inflammatory Bowel Disease and its Relevant Colorectal Cancer

Inflammatory bowel disease-associated colorectal cancer negatively affects surgery outcomes and health care costs

Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study

S1358 Black Patients with Inflammatory Bowel Disease are Less Likely to Reach Therapeutic Titers of Adalimumab Upon Initial Testing

S2036 Association Between Statin Use and Clinical Outcomes in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Propensity Score-Matched Analysis

Treat-to-Target and Regular Surveillance of Inflammatory Bowel Disease Are Associated with Low Incidence and Early-Stage Detection of Malignancies: A Retrospective Cohort Study